Riik: Lõuna-Aafrika Vabariik
keel: inglise
Allikas: South African Health Products Regulatory Authority (SAHPRA)
Lennon
TRIAZINE TABLETS SCHEDULING STATUS: S2 PROPRIETARY NAME (and dosage form): TRIAZINE TABLETS COMPOSITION: Each tablet contains Cyclizine hydrochloride 50 mg. PHARMACOLOGICAL CLASSIFICATION: A 5.7.2 Anti-emetics and anti-vertigo preparations. PHARMACOLOGICAL ACTION: Cyclizine, a piperazine derivative, is a first generation H1-receptor antagonist. Cyclizine diminishes or abolishes the main action of histamine in the body by competitive, reversible blockade of histamine receptor sites on tissue. It possesses both anticholinergic and anti-emetic activity. The exact mechanism by which it suppresses nausea and vomiting is unknown. It increases lower oesophageal sphincter tone and reduces sensitivity of the labyrinthe apparatus. It may also inhibit part of the midbrain known as the emetic centre. Cyclizine is well absorbed with peak plasma concentration achieved within 2 to 3 hours and a duration of action of 4 to 6 hours. It is widely distributed throughout the body including the central nervous system and is extensively metabolized mostly to the N-Demethylated derivative, Norcyclizine which has little (H1) antihistaminc activity and has a plasma elimination half-life of approximately 20 hours. INDICATIONS: Prophylaxis and treatment of motion sickness, accompanying air, sea or land travel. Triazine is also used for the symptomatic treatment of vertigo due to Ménières disease. CONTRA-INDICATIONS: - In patients who previously reacted adversely to cyclizine. - Safety in pregnancy and lactation has not been established. - During acute attacks of asthma, narrow angle glaucoma, urinary retention, prostatic hypertrophy, emphysema, chronic pulmonary disease, shortness of breath, difficulty in breathing, unless directed by a physican. - Should be avoided in cases of cardiovascular disease, liver disease Lugege kogu dokumenti